-
1
-
-
0015750131
-
Complement-tixing antibodies against cytomegalovirus in different parts of the world
-
1. Krech U. Complement-tixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 1973; 49:103-6.
-
(1973)
Bull World Health Organ
, vol.49
, pp. 103-106
-
-
Krech, U.1
-
2
-
-
0022253467
-
Epidemiology and transmission of cytomegalovirus
-
2. Pass RF. Epidemiology and transmission of cytomegalovirus. J Infect Dis 1985; 152:243-8.
-
(1985)
J Infect Dis
, vol.152
, pp. 243-248
-
-
Pass, R.F.1
-
3
-
-
0026513987
-
The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
-
3. Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. New Engl J Med 1992; 326:663-7.
-
(1992)
New Engl J Med
, vol.326
, pp. 663-667
-
-
Fowler, K.B.1
Stagno, S.2
Pass, R.F.3
-
4
-
-
0030054164
-
Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplantation recipients
-
4. Badley AD, Patel R, Portela DF, et al. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplantation recipients. J Infect Dis 1996; 173:446-9.
-
(1996)
J Infect Dis
, vol.173
, pp. 446-449
-
-
Badley, A.D.1
Patel, R.2
Portela, D.F.3
-
5
-
-
0025757384
-
Cytomegalovirus infection in heart-lung transplant recipients: Risk factors, clinical associations and response to treatment
-
5. Smyth RL, Scott JP, Borysiewicz LK, et al. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations and response to treatment. J Infect Dis 1991; 164:1045-50.
-
(1991)
J Infect Dis
, vol.164
, pp. 1045-1050
-
-
Smyth, R.L.1
Scott, J.P.2
Borysiewicz, L.K.3
-
6
-
-
0023909230
-
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): Clinical findings, diagnosis, and treatment
-
6. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988; 108:585-94.
-
(1988)
Ann Intern Med
, vol.108
, pp. 585-594
-
-
Jacobson, M.A.1
Mills, J.2
-
7
-
-
0026572259
-
Symptomatic congenital cytomegalovirus infection: Neonatal morbidity and mortality
-
7. Boppana SB, Pass RF, Britt WJ, et al., Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality, Pediatr Infect Dis J 1992; 11:93-9.
-
(1992)
Pediatr Infect Dis J
, vol.11
, pp. 93-99
-
-
Boppana, S.B.1
Pass, R.F.2
Britt, W.J.3
-
8
-
-
0019177299
-
Outcome of symptomatic congenital cytomegalovirus infection: Results of long-term longitudinal follow-up
-
8. Pass RF, Stagno S, Myers GJ, et al. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics 1980; 66:758-62.
-
(1980)
Pediatrics
, vol.66
, pp. 758-762
-
-
Pass, R.F.1
Stagno, S.2
Myers, G.J.3
-
9
-
-
0015938363
-
Inapparent congenital cytomegalovirus infection: A follow-up study
-
9. Kumar ML, Nankervis GA, Gold E. Inapparent congenital cytomegalovirus infection: a follow-up study. N Engl J Med 1973; 288:1370-2.
-
(1973)
N Engl J Med
, vol.288
, pp. 1370-1372
-
-
Kumar, M.L.1
Nankervis, G.A.2
Gold, E.3
-
10
-
-
0023677488
-
Induction of complement-dependent and independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55 116 (gB)
-
10. Britt WJ, Vugler L, Stephens EB. Induction of complement-dependent and independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55 116 (gB). J Virol 1988; 62:3309-18.
-
(1988)
J Virol
, vol.62
, pp. 3309-3318
-
-
Britt, W.J.1
Vugler, L.2
Stephens, E.B.3
-
11
-
-
0029422476
-
Selection of potent immunological adjuvants for vaccine construction
-
11. McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Sem Cancer Biol 1995; 6:375-85.
-
(1995)
Sem Cancer Biol
, vol.6
, pp. 375-385
-
-
McElrath, M.J.1
-
12
-
-
0028034562
-
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules
-
NIAID AIDS Vaccine Clinical Trials Network
-
12. Gorse GJ, Schwartz DH, Graham BS, et al. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. Clin Exp Immunol 1994; 98:178-84.
-
(1994)
Clin Exp Immunol
, vol.98
, pp. 178-184
-
-
Gorse, G.J.1
Schwartz, D.H.2
Graham, B.S.3
-
13
-
-
0028817215
-
Cervical but not urinary excretion of cytomegalovirus is related to sexual activity and contraceptive practices in sexually active women
-
13. Collier AC, Handsfield HH, Ashley R. Cervical but not urinary excretion of cytomegalovirus is related to sexual activity and contraceptive practices in sexually active women. J Infect Dis 1995; 171:33-8.
-
(1995)
J Infect Dis
, vol.171
, pp. 33-38
-
-
Collier, A.C.1
Handsfield, H.H.2
Ashley, R.3
-
14
-
-
0026026599
-
Cytomegalovirus infection in sexually active adolescents
-
14. Sohn YM, Oh MK, Balcarek KB, et al. Cytomegalovirus infection in sexually active adolescents. J Infect Dis 1991; 163:460-3.
-
(1991)
J Infect Dis
, vol.163
, pp. 460-463
-
-
Sohn, Y.M.1
Oh, M.K.2
Balcarek, K.B.3
|